Targeting M1—The Agony of Agonists, the Power of Potentiators
see Conn et al., 2009 and Fisher, 2008).—Esther Landhuis None
379 RESULTS
You searched Esther
Sort By:
see Conn et al., 2009 and Fisher, 2008).—Esther Landhuis None
assay.”—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=3259 Alzheimer's Disease Biomarkers
the authors write.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=2580
mimic Aβ40 in its ability to prevent Aβ42 aggregation.—Esther Landhuis None
told ARF his team may examine Aβ42 oligomerization in future studies.—Esther Landhuis. None
Germany.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=2447 Alzheimer's Disease Early Onset
fully effective against late-onset AD.”—Esther Landhuis None
biology there.”—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=1918 Alzheimer's
earlier this fall, and should be completed by late 2011, Koenig said.—Esther Landhuis. None
with this reporter.—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=2193
the ApoE4 protein,” they wrote in an e-mail to ARF (see full comment below).—Esther Landhuis None
neurodegeneration.”—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=2316 Alzheimer's Disease Clinical
fragments (see ARF related conference story).—Esther Landhuis None
AD/neurodegeneration.”—Esther Landhuis None http://www.alzforum.org/new/detail.asp?id=2581 Alzheimer's Disease Glutamate
more than 10 percent by 2050 (Brookmeyer et al., 2007).—Esther Landhuis None